GSK3B and prostate carcinoma: Troglitazone inhibited the constitutive expression of GSK-3β and activation of NFκB. Cotreatment of troglitazone with a GSK-3β inhibitor (AR-a014418) or GSK-3β siRNA significantly augmented the inhibitory effect of troglitazone on the NFκB activity and on prostate cancer cell growth inhibition and apoptotic cell death.